Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174983
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPölzl, Gerhard-
dc.contributor.authorAllipour Birgani, Shadad-
dc.contributor.authorComín Colet, Josep-
dc.contributor.authorDelgado, Juan F.-
dc.contributor.authorFedele, Francesco-
dc.contributor.authorGarcía Gonzáles, Martín J.-
dc.contributor.authorGustafsson, Finn-
dc.contributor.authorMasip, Josep-
dc.contributor.authorPapp, Zoltán-
dc.contributor.authorStörk, Stefan-
dc.contributor.authorUlmer, Hanno-
dc.contributor.authorVrtovec, Bojan-
dc.contributor.authorWikström, Gerhard-
dc.contributor.authorAltenberger, Johann-
dc.date.accessioned2021-03-12T11:54:24Z-
dc.date.available2021-03-12T11:54:24Z-
dc.date.issued2018-10-30-
dc.identifier.issn2055-5822-
dc.identifier.urihttp://hdl.handle.net/2445/174983-
dc.description.abstractHospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherJohn Wiley & Sons-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/ehf2.12366-
dc.relation.ispartofESC Heart Failure, 2018, vol. 6, num. 1, p. 174-181-
dc.relation.urihttps://doi.org/10.1002/ehf2.12366-
dc.rightscc-by-nc-nd (c) Pölzl, Gerhard et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationInsuficiència cardíaca-
dc.subject.classificationAssaigs clínics-
dc.subject.classificationFactors de risc en les malalties-
dc.subject.classificationMalalts hospitalitzats-
dc.subject.otherHeart failure-
dc.subject.otherClinical trials-
dc.subject.otherRisk factors in diseases-
dc.subject.otherHospital patients-
dc.titleRepetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec702597-
dc.date.updated2021-03-12T11:54:24Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30378288-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
702597.pdf301.53 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons